Article | 10-April-2021
Wra is the most common low-prevalence antigen (LPA) in the white population, and anti-Wra is the most common naturally occurring antibody.1 The first case of anti-Wra was described by Holman2 in 1953 in a child with severe hemolytic disease of the fetus and newborn (HDFN), requiring exchange transfusion. Anti-Wra is often identified when Wr(a+) red blood cells (RBCs) are available on the screening or identification panel RBCs, but the antibody is otherwise rarely involved in serious hemolytic
A. Espinosa,
L.J. Garvik,
N. Trung Nguyen,
B. Jacobsen
Immunohematology, Volume 37 , ISSUE 1, 20–24
Case report | 09-October-2019
(RBCs) in the apheresis unit as part of her regular treatment. When the patient started receiving the implicated unit, she reported back pain, chest pain, and a feeling of anxiety, suggestive of an acute transfusion reaction. The transfusion was ceased and an investigation of an adverse event was commenced. This case illustrates that the presence of antibodies to low-prevalence antigens remains a significant issue for transfusion-dependent individuals. To prevent other transfusion reactions by anti
Arthur J. Joyce,
Kelli M Quantock,
Ray Banh,
Yew-Wah Liew
Immunohematology, Volume 33 , ISSUE 1, 6–8
Case report | 24-March-2020
Wra is a low-prevalence antigen. Anti-Wra is a relatively common antibody present in approximately 1 in 100 healthy blood donors. Anti-Wra is reported to cause different degrees of hemolysis in transfusion and in HDN, ranging from benign to severe. This report describes an acute overt hemolytic transfusion reaction in a patient whose serum contained anti-Wra and who received a Wr(a+) RBC component.
Fouad N. Boctor
Immunohematology, Volume 24 , ISSUE 3, 113–115
Case report | 26-October-2019
Ashwini Bennett,
Ray K. Boyapati,
Frank S. Hong
Immunohematology, Volume 31 , ISSUE 4, 163–165
Report | 11-March-2020
Nancy M. Nikolis,
Fouad Boctor,
William Andrew Heaton,
James Martone
Immunohematology, Volume 27 , ISSUE 3, 104–106
Report | 01-December-2019
Christine Halter Hipsky,
Daiane Cobianchi da Costa,
Ricardo Omoto,
Angela Zanette,
Lilian Castilho,
Marion E. Reid
Immunohematology, Volume 27 , ISSUE 2, 66–67
Review | 09-October-2019
Annika K. Hult,
Martin L. Olsson
Immunohematology, Volume 33 , ISSUE 2, 64–72
Review | 01-December-2019
The Diego blood group system (DI) currently encompasses 22 antigens. Three of the antigens are of high prevalence and the other 19 are of low prevalence. The antigens of the Diego blood group system are carried on the erythroid band 3 protein anion exchanger 1 (AE1), the product of a single gene, SLC4A1 (solute carrier family 4, anion exchanger, member 1). AE1 is a member of a family of three anion exchangers or transporters expressed in a variety of tissues. This protein is involved in carbon
Dolores Figueroa
Immunohematology, Volume 29 , ISSUE 2, 73–81
Review | 12-March-2020
Antigens in the Gerbich blood group system are expressed on glycophorin C (GPC) and glycophorin D (GPD), which are both encoded by a single gene, GYPC. The GYPC gene is located on the long arm of chromosome 2, and Gerbich antigens are inherited as autosomal dominant traits. There are 11 antigens in the Gerbich blood group system, six of high prevalence (Ge2, Ge3, Ge4, GEPL [Ge10*], GEAT [Ge11*], GETI [Ge12*]) and five of low prevalence (Wb [Ge5], Lsa [Ge6], Ana [Ge7], Dha [Ge8], GEIS [Ge9
Phyllis S. Walker,
Marion E. Reid
Immunohematology, Volume 26 , ISSUE 2, 60–65
Review | 20-March-2020
The MNS blood group system is second only to the Rh blood group system in its complexity. Many alloantibodies to antigens in the MNS system are not generally clinically significant although antibodies to low-prevalence and high-prevalence MNS antigens have caused hemolytic disease of the fetus and newborn. The MNS antigens are carried on glycophorin A (GPA), glycophorin B (GPB), or hybrids thereof, which arise from single-nucleotide substitution, unequal crossing over, or gene conversion
Marion E. Reid
Immunohematology, Volume 25 , ISSUE 3, 95–101
Article | 21-April-2020
The Cromer blood group system consists of nine high-prevalence and three low-prevalence antigens carried on decay-accelerating factor (DAF). We recently described one of these Cromer highprevalence antigens,SERF,the absence of which was found in a Thai woman.The lack of SERF antigen in this proband was associated with a substitution of nucleotide 647C>T in exon 5 of DAF, which is predicted to be a change of proline to leucine at amino acid position 182 in short consensus repeat (SCR) 3 of
Poonsub Palacajornsuk,
Kim Hue-Roye,
Oytip Nathalang,
Srisurang Tantimavanich,
Sasitorn Bejrachandra,
Marion Reid
Immunohematology, Volume 21 , ISSUE 2, 66–69
Article | 21-April-2020
The Cromer blood group system consists of ten high-prevalence and three low-prevalence antigens carried on decay-accelerating factor (DAF). DAF is found in the cell membranes of RBCs, granulocytes,platelets,and lymphocytes and is widely represented in other body tissues. Sequence analyses of DNA were performed on a blood sample from a 91-year-old Japanese woman whose serum contained an alloantibody to a high-prevalence antigen in the Cromer blood group system (anti-IFC). A blood sample from her
Kim Hue-Roye,
Vivien E. Powell,
Gita Patel,
Debra Lane,
Mariska Maguire,
Amy Chung,
Marion E. Reid
Immunohematology, Volume 21 , ISSUE 2, 53–55
Review | 21-April-2020
The antigens of the Cromer blood group system are located on the protein decay-accelerating factor (DAF). This system consists of ten high-prevalence and three low-prevalence antigens; the molecular basis for all of these antigens is a single nucleotide polymorphism in the DAF gene. DAF is a 70,000-Da plasma membrane protein that is widely distributed on all blood cells and on endothelial and epithelial tissues. The physiological role of DAF is to inhibit the complement cascade at the level of
Douglas M. Lublin
Immunohematology, Volume 21 , ISSUE 2, 39–47
Article | 15-February-2021
lacking low-prevalence antigens. An important recent report of an acute hemolytic transfusion reaction due to anti-Sc2 provides an excellent example of the potential adverse consequences of categorizing low-prevalence antibodies as “clinically insignificant.”10 In their patient with a previously identified anti-Sc2, electronic or immediate-spin crossmatches were performed rather than compatibility testing using an indirect antiglobulin test because of an assumption that anti-Sc2 was not clinically
P.A.R. Brunker,
W.A. Flegel
Immunohematology, Volume 35 , ISSUE 2, 48–50
Article | 01-April-2020
The low-prevalence MNS blood group antigenTSEN is located at the junction of glycophorinA (GPA) to glycophorin B (GPB) in several hybrid glycophorin molecules. Extremely rare people have RBCs with a double dose of theTSEN antigen and have made an antibody to a high-prevalence MNS antigen. We report the first patient who is heterozygous for GYP.JL and Mk. During prenatal tests,an alloantibody to a high-prevalence antigen was detected in the serum of a 21-year-old Hispanic woman. The antibody
John Ratliff,
Susan Veneman,
Joan Ward,
Christine Lomas-Francis,
Kim Hue-Roye,
Randall W. Velliquette,
Laima Sausais,
Twilla Maldonado,
Janet Miyamoto,
Yolanda Martin,
David Slater,
Marion E. Reid
Immunohematology, Volume 23 , ISSUE 4, 146–149
Original Paper | 04-December-2017
Middle East and North Africa (MENA) new HIV cases show the highest increase among all regions in the world. Even though Egypt has a low prevalence among the general population (< 0.02%), a national HIV epidemic occurs in certain population risk groups. The current study was conducted to asses clinical and immunological disease progression; following up viral load (VL) and detecting delta-32 CCR5 genotype polymorphism in selected cases, determining unemployment rate and identify predictors of
Faika M. Ghoneim,
May M. Raouf,
Noha S. Elshaer,
Sarah M. Abdelhamid,
Reem A. Noor Eldeen
Polish Journal of Microbiology, Volume 66 , ISSUE 4, 519–527
Article | 17-February-2021
The Indian blood group antigen Ina was recognized in the early 1970s when an antibody to a low-prevalence antigen was assigned the symbol after the name of the country where it was first found.1 It received blood group system status after its antithetical antibody, called Salis, directed to a high-prevalence antigen (HPA) was reviewed and renamed as Inb.2 The system was further expanded when four more HPAs, namely, INFI, INJA, INRA, and INSL, were found befitting to the system.3–5 Although Ina
S.R. Joshi,
S.B. Senjaliya,
K. Srivastava,
W.A. Flegel
Immunohematology, Volume 36 , ISSUE 4, 129–132